Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Combos in Pediatric/Young Adult Cancers (LIGHTBEAM-U01 Substudy 01B)
NCT06395090Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of favezelimab, vibostolimab in classical Hodgkin lymphoma (cHL), solid tumor, sponsored by Merck & Co.. Planned start Jan 2025; status: withdrawn.
02
Drugs
favezelimabvibostolimab
03
Conditions
classical Hodgkin lymphoma (cHL)solid tumor
Beyond the preview
Go deeper on NCT06395090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395090.